All lobbying filings

Holland & Knight LLP

Holland & Knight LLP filed a Q3 report for Novo Nordisk, Inc. on October 17, 2026, reporting $60,000 in lobbying income.

Lobbying for Novo Nordisk, Inc. · Pharmaceutical company

As filed: HOLLAND & KNIGHT LLP for NOVO NORDISK, INC.

All filings by Holland & Knight LLP · Everything Novo Nordisk, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 17, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Budget/Appropriations

Legislation related to obesity treatments; Advocacy for antiobesity medications.

Health Issues

Legislation related to obesity treatments; Advocacy for antiobesity medications.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.